EV3 and FoxHollow Merger Establishes Peripheral Leader
FoxHollow's striking success in peripheral vascular disease was not lost on EV3, which, like FoxHollow, abandoned earlier efforts in coronaries to focus exclusively on peripherals. Now the companies are merging to form what is surely the biggest vascular device company dedicated to the peripheral market. (Sidebar to, "EV3/Novation: Can Group Contracting Work in High Tech?")
You may also be interested in...
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Nutritional Brands rolls out NB Pure as brand, including logo, packaging design and website, for all its supplements after 25 years. “When you looked at our label for one brand and looked at the label for another brand, there was no symmetry between the two,” says CEO Danna Pratt.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.